Conference Announcement | Hycells cordially invites you to join the 3rd Boao Lecity Stem Cell Summit
Release Date:
2026-03-09 16:48
Conference Background
From March 20 to 22, 2026, the Third Boao Lecity Stem Cell Conference, co-hosted by the China Anti-Aging Promotion Association and Hainan University, will be held in Boao Lecity, Hainan. With the theme “Cell Therapy Pioneering the Third Medical Revolution,” the conference will also make a major announcement of the latest batch of cell therapy procedures that are now permitted to be billed, thereby establishing an international high-end platform that brings together cutting-edge ideas, translates research into clinical practice, fosters industry collaboration, and jointly develops policies and standards.
Basic Conference Information
Conference Name: The 3rd Boao Lingshui Stem Cell Conference
Meeting Theme: Cell Therapy Leads the Third Medical Revolution
Meeting Time: March 20–22, 2026
Meeting Location: Boao Lucheng Yihhe Health and Wellness Resort
Conference Organizational Structure
Organizer: China Anti-Aging Promotion Association, Hainan University
Introduction to Hycells
At the Third Boao Lecheng Stem Cell Conference, government authorities provided an in-depth analysis of the approval policies for cell therapy pricing items, the regulatory framework, and future directions for policy adjustments. Leading Nobel laureates presented the latest advances in global basic stem cell research and translational medicine, highlighting the core breakthroughs driving the third medical revolution through cell therapy and outlining future strategic priorities, thereby offering a comprehensive overview of cutting-edge developments and the sector’s long-term vision. As a pioneering company in primary cell technology, Hycells Biotechnology was also invited to attend the conference.
Wuxi Hycells Biotechnology Co., Ltd. (hereinafter referred to as “Hycells Bio”) is a high-tech enterprise specializing in primary immune cell and stem cell technologies, with its headquarters located in the Wuxi Precision Medicine Industrial Park. The company has established a comprehensive, end-to-end technology platform covering both immune cells and mesenchymal stem cells (MSCs). Leveraging a dual-center operational model centered on Wuxi and Shanghai, Hycells Bio strengthens its R&D and translational capabilities: the Wuxi center focuses on product development, manufacturing, and commercialization, while the Shanghai center specializes in the preparation of primary cells and related technical services.
Adhering to the R&D philosophy of “end-to-end process optimization” and “integrated technology,” Hycells Biotechnology has launched a benchmark one-stop culture solution for immune cells and stem cells, creating a comprehensive offering that includes compliant seed cells and HiXpan. Registered trademark Serum-free culture kit, HiXpan Registered trademark An integrated cell culture system that combines cell culture supplements and the four core components of Cell Feeder底透 cell culture flasks, providing customers with efficient, stable, and compliant end-to-end culture support.
Meanwhile, the company continues to expand its product portfolio and service capabilities centered on primary cell technology, having established a business footprint focused on primary immune cells, stem cells, and hepatocytes, which has given rise to HiXpan. Registered trademark The product portfolio includes cell culture kits, the HiMag magnetic bead-based sorting kit series, as well as assay products such as CAR-positive rate detection kits and ELISpot assay kits. In terms of technical services, Hycells Biotechnology offers specialized solutions covering in vitro efficacy evaluation, drug immunogenicity assessment, and hematotoxicity testing, providing precise support for critical stages in biopharmaceutical R&D and manufacturing. Several of its products and services have broken long-standing foreign monopolies, achieving domestic innovation and surpassing international standards, thereby delivering comprehensive, independently controllable solutions to the industry.
Hycells’s star product
HiXpan Registered trademark MSC Serum-Free Culture Kit
FIRE FIGHTING
High-cell yield
High exosome yield
A high-quality, complete culture protocol specifically designed for the primary isolation and serial passaging of human mesenchymal stem cells under serum-free, xeno-free conditions.
Product Advantages:
Safety: Serum-free and free of xenogenic components
Broad-spectrum: Applicable to mesenchymal stem cells derived from multiple tissue sources, such as umbilical cord MSCs, bone marrow MSCs, and adipose-derived MSCs.
High efficiency: faster proliferation, stable passage for more than 10 passages, and better maintenance of cellular differentiation potential.
Convenience: Direct use—no need to add any additional components or coat the microtiter plates.
HiXpan Registered trademark NK Cell Serum-Free Culture Kit (Cytokine-Based)
FIRE FIGHTING
High purity, high amplification efficiency
Efficient induction and expansion of NK cells from human peripheral blood or umbilical cord blood-derived samples.
Product Advantages:
Strong expansion capacity: cells can be expanded up to 500-fold, with a post-expansion viability of ≥90%.
NK cells exhibit high purity and potent cytotoxic activity.
Suitable for fresh or cryopreserved PBMCs and CBMCs.
GMP-grade culture media: safe, stable, and highly efficient.
No antibody coating required; simple and convenient operation.
HiXpan Registered trademark Cell culture
Additives
FIRE FIGHTING
Single donor traceability
Additives with well-defined biological compositions and no animal-derived sources, used in cell culture as substitutes for traditional animal sera such as fetal bovine serum, are designed to reduce batch-to-batch variability, minimize contamination risks, and enhance experimental reproducibility. Their formulations typically include growth factors, carrier proteins, trace elements, and other components, making them suitable for applications in vaccine production, biopharmaceuticals, regenerative medicine, and other fields.
Product Advantages:
Compliance and Traceability: Material sources are compliant and traceable, and suppliers have established independent information traceability documentation and systems.
High performance: Utilizes a proprietary, in-house process to release high-concentration growth factors, significantly accelerating cell proliferation.
Compliant with GMP and regulatory requirements: supports IND submissions and IIT clinical studies.
Meeting Agenda and Procedure
Specialized Forum
1. Special Forum on Cell Therapy for Neurological Disorders
Forum Chair: Li Wenbin
2. Special Forum on Immunocellular Therapy for Diseases
Forum Chair: Wei Yuquan
3. Special Forum on Cell Therapy for Immune Diseases
Forum Chair: Wu Yuzhang
4. Special Forum on Cell Therapy for Women’s Diseases
Forum Chair: Qiao Jie
5. Special Forum on Cell Therapy for Liver Diseases and Major Infectious Diseases
Forum Chair: Wang Fusheng
6. Special Forum on Cell Therapy for Endocrine Diseases
Forum Chair: Deng Hongkui’s Team
7. Oncolytic Virus Symposium
Forum Chair: Shang Yongfeng
Related News
818 Breakthrough Technology | Integrated Culture Protocol for γδ T Cells
The implementation of the “818 Regulations” marks the official entry of China’s cell therapy industry into a new phase of standardized development, one that prioritizes clinical efficacy as the benchmark for value, upholds rigorous compliance across the entire value chain as an inviolable baseline, and harnesses differentiated technological innovation as the core driver of progress. The Regulations explicitly restrict low-level duplication and homogeneous competition, while giving priority to the translation of technology pathways that demonstrate clear clinical value and outstanding scientific innovation, thereby establishing clear compliance boundaries and a well-defined innovation orientation for the industry’s future development.
Conference Announcement | Hycells cordially invites you to join the 3rd Boao Lecity Stem Cell Summit
From March 20 to 22, 2026, the Third Boao Lecity Stem Cell Conference, co-hosted by the China Anti-Aging Promotion Association and Hainan University, will be held in Boao Lecity, Hainan. With the theme “Cell Therapy Pioneering the Third Medical Revolution,” the conference will also make a major announcement of the latest batch of cell therapy procedures that are now permitted to be billed, thereby establishing an international high-end platform that brings together cutting-edge ideas, translates research into clinical practice, fosters industry collaboration, and jointly develops policies and standards.
A Tribute to the Woman Who Provides “Cell-Level” Protection in the Field of Life Sciences
In the world of biopharmaceuticals, cells are the fundamental units of life; at Hycells Biotechnology, women are the driving force behind global progress. From relentless pursuit in the laboratory to compassionate care on the clinical front lines, women’s sensitivity, resilience, and wisdom—like the “primary cell” technology we have meticulously cultivated—harness the most primal and essential power to propel innovation and shape the future of our field.
Hycells Biotechnology is a biotechnology innovation company specializing in research on primary immune cells and hepatocytes. We are committed to providing customers with comprehensive, one-stop solutions for immune cells and stem cells, leveraging scientific innovation to drive industry development and delivering expert services to empower clinical research.
3.0 High-Efficiency NK Serum-Free Culture Kit | Chapter 1: Cord Blood–Derived CBNK
Hycells Biotechnology’s newly launched 3.0 High-Efficiency Serum-Free NK Cell Culture Kit (Catalog No.: NK888-2L), in collaboration with the CBMC Seed Bank, provides a comprehensive, integrated cell culture solution: from thawing and recovering CBMC seed stocks or directly and efficiently expanding fresh CBMCs, to ultimately obtaining NK cells with high purity and high viability. This integrated culture system supports flexible expansion based on cell status, with a scalable culture volume of up to 10 liters, delivering outstanding culture performance and exceptional cost-effectiveness, and earning widespread trust and recognition from customers.
New Product | Hycells Announces the Launch of High-Viability Primary Hepatocyte Cells!
Within 4 hours after recovery, its cytochrome P450 enzyme activity is most similar to that in vivo, making it suitable for short-term metabolic studies.